Single-Cell Transcriptome Analysis of Radiation Pneumonitis Mice

Yang, Miaomiao; Fan, Qiang; Hei, Tom K.; Chen, Guodong; Cao, Wei; Ma, Gang; Han, Wei

doi:10.3390/antiox11081457

Cited by 13 publications

(8 citation statements)

References 68 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…4g). Downregulation of the Hbb-bt and Hba-at genes may involve the evasion of ROS-mediated antioxidants in NK cells [52,53]. To further con rm this nding, we identi ed that the activation of BCl2 (anti-apoptotic protein) (Fig.…”

Section: Nk Cell Subsets Induced Pro-in Ammatory Response After Treat...mentioning

confidence: 80%

Deciphering the Immunotoxicity of Titanium Dioxide Nanoparticles (E171) in Mouse Leukocytes through Single-Cell RNA Sequencing

Perumalsamy,

Xiao,

Han

et al. 2024

Preprint

View full text Add to dashboard Cite

The cellular and immunological responses in the immune system after exposure to TiO2 NPs/E171 are poorly understood. Therefore, comprehensive single-cell RNA-seq (scRNA-seq) analysis was used to explore the unique heterogeneous response upon TiO2 NPs/E171 treatment in Sprague-Dawley rats. Firstly, granulocyte G1 activated innate immune response through the upregulation of genes involved in pro-inflammatory cytokine mediated cytotoxicity. Whereas NK cells resulted in heterogeneity role depending on the subsets where NK1 significantly inhibited cytotoxicity, whereas NK2 and NK3 subsets activated pro-B cell population & inhibited T cell mediated cytotoxicity respectively. While NKT_1 activated innate inflammatory responses which was confirmed by cytotoxic CD8 + T killer cell suppression. Similarly, NKT_2 cells promote inflammatory response by releasing lytic granules and MHC-I complex inhibition to arrest cytotoxic T killer cell responses. Conversely, NKT_3 suppressed inflammatory response by release of anti-inflammatory cytokines suggesting the functional heterogeneity of NKT subset. The formation of MHC-I or MHC-II complexes with T-cell subsets resulted in neither B and T cell dysfunction nor cytotoxic T killer cell inhibition suppressing adaptive immune response. This study not only masks the drawbacks of utilizing homogeneous immune cell types, but also provides a full understanding of high-dimensional heterogeneous immunological response at the single cell level.

show abstract

Section: Nk Cell Subsets Induced Pro-in Ammatory Response After Treat...mentioning

confidence: 80%

Deciphering the Immunotoxicity of Titanium Dioxide Nanoparticles (E171) in Mouse Leukocytes through Single-Cell RNA Sequencing

Perumalsamy,

Xiao,

Han

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

“…MHC-I expression on the surface of the tumor cells and the ability of dendritic cells (DCs) to present antigens can be increased after radiation. Miaomiao Yang et al proposed that RP tissue had less naive CD8 + T cells, more effector T cells, and a more diverse B cell subtype [35]. Based on available evidence, radiation-induced RP can activate the immune response to some extent, which could be bene cial for the survival of lung cancer patients.…”

Section: Discussionmentioning

confidence: 99%

The radiotherapy planning CT-based multi-omics for predicting the radiation pneumonitis in lung cancer patients: A multi-center study

Niu

Chu

Yang

et al. 2023

Preprint

View full text Add to dashboard Cite

Background To predict the risk of radiation pneumonitis (RP), deep learning (DL) models were built to stratify lung cancer patients. Our study also investigated the impact of RP on survival. Methods This study retrospectively collected 100 RP and 99 matched non-RP lung cancer patients treated with radiotherapy from two independent centers. These patients were randomly divided into training (n = 175) and validation cohorts (n = 24). The radiomics and dosiomics features were extracted from radiation planning computed tomography (CT). Clinical information was retrospectively collected from the electronic medical record database. All features were screened by LASSO cox regression. A multi-omics prediction model was developed by the optimal algorithm and estimated the area under the receiver operating characteristic curve (AUC). Overall survival (OS) between RP, non-RP, mild-RP, and severe-RP groups was analyzed by the Kaplan-Meier method. Results There were eventually selected 16 radiomics features, 2 dosiomics features, and 1 clinical feature to build the best multi-omics model. GLRLM_Gray Level Non Uniformity Normalized and GLCM_MCC from PTV were essential dosiomics features, and T stage was a paramount clinical feature. The optimal performance for predicting RP was the AUC of testing set [0.94, 95% confidence interval (CI) (0.939-1.000)] and the AUC of external validation set [0.92, 95% CI (0.80-1.00)]. All RP patients were divided into mild-RP and severe-RP group according to RP grade (≤ 2 grade and > 2 grade). The median OS was 31 months (95% CI, 28–39) for non-RP group compared with 49 months (95% CI, 36-NA) for RP group (HR = 0.53, P = 0.0022). Among RP subgroup, the median OS was 57months (95% CI, 47-NA) for mild-RP and 25 months (95% CI, 29-NA) for severe-RP, and mild-RP group exhibited a longer OS (HR = 3.72, P < 0.0001). Conclusion The multi-omics model contributed to improvement in the accuracy of the RP prediction. Interestingly, this study also demonstrated that compared with non-RP patients, RP patients displayed longer OS, especially mild-RP.

show abstract

“…A recent study showed that the cGAS/STING pathway is enriched in radiation-induced fibrosis [ 142 ]. Furthermore, the role of the STING pathway in liver, kidney and lung fibrosis has also been demonstrated [ 143 – 145 ].…”

Section: Mechanisms Of Radiation-induced Fibrosismentioning

confidence: 99%

Tissue fibrosis induced by radiotherapy: current understanding of the molecular mechanisms, diagnosis and therapeutic advances

Yu,

Xu,

Song

et al. 2023

J Transl Med

View full text Add to dashboard Cite

Cancer remains the leading cause of death around the world. In cancer treatment, over 50% of cancer patients receive radiotherapy alone or in multimodal combinations with other therapies. One of the adverse consequences after radiation exposure is the occurrence of radiation-induced tissue fibrosis (RIF), which is characterized by the abnormal activation of myofibroblasts and the excessive accumulation of extracellular matrix. This phenotype can manifest in multiple organs, such as lung, skin, liver and kidney. In-depth studies on the mechanisms of radiation-induced fibrosis have shown that a variety of extracellular signals such as immune cells and abnormal release of cytokines, and intracellular signals such as cGAS/STING, oxidative stress response, metabolic reprogramming and proteasome pathway activation are involved in the activation of myofibroblasts. Tissue fibrosis is extremely harmful to patients' health and requires early diagnosis. In addition to traditional serum markers, histologic and imaging tests, the diagnostic potential of nuclear medicine techniques is emerging. Anti-inflammatory and antioxidant therapies are the traditional treatments for radiation-induced fibrosis. Recently, some promising therapeutic strategies have emerged, such as stem cell therapy and targeted therapies. However, incomplete knowledge of the mechanisms hinders the treatment of this disease. Here, we also highlight the potential mechanistic, diagnostic and therapeutic directions of radiation-induced fibrosis.

show abstract

Single-Cell Transcriptome Analysis of Radiation Pneumonitis Mice

Cited by 13 publications

References 68 publications

Deciphering the Immunotoxicity of Titanium Dioxide Nanoparticles (E171) in Mouse Leukocytes through Single-Cell RNA Sequencing

Deciphering the Immunotoxicity of Titanium Dioxide Nanoparticles (E171) in Mouse Leukocytes through Single-Cell RNA Sequencing

The radiotherapy planning CT-based multi-omics for predicting the radiation pneumonitis in lung cancer patients: A multi-center study

Tissue fibrosis induced by radiotherapy: current understanding of the molecular mechanisms, diagnosis and therapeutic advances

Contact Info

Product

Resources

About